Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01981954
Other study ID # 905-CL-074
Secondary ID 2012-003178-22
Status Completed
Phase Phase 3
First received
Last updated
Start date September 25, 2013
Est. completion date December 18, 2015

Study information

Verified date October 2018
Source Astellas Pharma Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to evaluate long term efficacy and safety of treatment with solifenacin succinate (the study drug) in children with neurogenic detrusor overactivity after multiple dose administration.


Description:

In some children with a severe form of spina bifida (which is the consequence of a spinal cord defect), the bladder muscle (detrusor) contracts strongly and without warning (also known as neurogenic detrusor overactivity) and the urethra (the passage connecting the bladder with outside) does not relax. Though these children cannot void, urine leakage can happen when the overactive contractions are strong, and/or the pressure in the bladder is so high that it overcomes the closed urethra (overflow at high filling bladder pressure). This high bladder pressure puts these children at risk for kidney damage and can decrease the quality of the bladder. Therapy was aimed to decrease the high filling bladder pressure and the overactive detrusor contractions.


Recruitment information / eligibility

Status Completed
Enrollment 23
Est. completion date December 18, 2015
Est. primary completion date December 18, 2015
Accepts healthy volunteers No
Gender All
Age group 6 Months to 4 Years
Eligibility Inclusion Criteria:

- Myelomeningocoele

- Documented diagnosis of NDO, confirmed by urodynamics

- DSD (detrusor sphincter dyssynergia)

- Practicing clean intermittent catheterization (CIC)

Exclusion Criteria:

- Know genitourinary condition (other than NDO) that may cause incontinence

- Bladder augmentation surgery

- Current faecal impaction

- Electro-stimulation therapy within 2 weeks prior to visit

- Subjects with the following gastro-intestinal problems: partial or complete obstructions, decreased motility like paralytic ileus, subjects at risk of gastric retention

- Reflux grade 3 to 5

- Current urinary tract infection

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Solifenacin succinate
Oral suspension

Locations

Country Name City State
Belgium Site BE3203 Gent University Hospital Gent
Korea, Republic of Site KR8201 Severance Hospital Seoul
Korea, Republic of Site KR8207 Seoul National University Hospital Seoul
Philippines Site PH6301 Philippines Children's Medical Center Manila
Poland Site PL4803 Uniwersyteckie Centrum Kliniczne Gdansk
Poland Site PL4801 Pomnik-Centrum Zdrowia Dziecka Warszawa
United Kingdom Site GB4401 Sheffield Children's Hospital Sheffield
United States Site US1008 Pediatric Urology Associates, P.C. Tarrytown New York

Sponsors (1)

Lead Sponsor Collaborator
Astellas Pharma Europe B.V.

Countries where clinical trial is conducted

United States,  Belgium,  Korea, Republic of,  Philippines,  Poland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change From Baseline to Week 24 in Maximum Cystometric Capacity (MCC) MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first), as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of expected bladder capacity [EBC] was reached for participants = 2 years or of maximum catheterized volume [MCV] for participants aged 6 months to < 2 years; the participants' bladder was emptied via catheterization). Baseline and Week 24
Secondary Change From Baseline to Weeks 3, 6, 9, 12 and 52 in MCC MCC was the volume instilled into the bladder prior to leakage or end of bladder-filling (whichever was reached first) as assessed by urodynamics (procedure: the bladder was to be filled until voiding/leakage began, or until it was stopped because either the participant experienced pain or discomfort or 135% of EBC was reached for participants = 2 years or of MCV for participants aged 6 months to < 2 years. The participants' bladder was emptied via catheterization). Baseline and Weeks 3, 6, 9, 12, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Compliance Bladder compliance gives an indication of the elasticity of the bladder wall. Bladder compliance was calculated by dividing the change in volume during the filling of the bladder by the change in detrusor pressure during that change in bladder volume using urodynamic assessments. The values for bladder volume and detrusor pressure at the beginning and end of filling were taken and used. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure at End of Bladder-Filling Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Detrusor Pressure 5 Minutes After End of Bladder-Filling Detrusor pressure was expressed as bladder pressure minus intra-abdominal pressure as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Catheterized Volume 5 Minutes After End of Bladder-Filling Catheterized volume was measured when the bladder was emptied via catheterization 5 minutes after the end of bladder-filling. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume Until First Detrusor Contraction (> 15 cmH2O) Bladder volume as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 10 cmH20 Detrusor Pressure Bladder volume as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 20 cmH20 Detrusor Pressure Bladder volume as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Bladder Volume at 30 cmH20 Detrusor Pressure Bladder volume as assessed by urodynamics. Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24 and 52 in Number of Overactive Detrusor Contractions (> 15 cmH2O) Until Leakage or End of Bladder-Filling Baseline and Weeks 3, 6, 9, 12, 24, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average Catheterized Volume Per Catheterization The average catheterized volume per catheterization was calculated using all available (non-zero) catheterized volumes recorded over both of the 2 measuring days in the diary, whether or not these 2 days were concurrent. Catheterized volumes were recorded for 2 days in a participant diary prior to each visit. Four to six catheterizations were performed every day. Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Maximum Catheterized Volume (MCV) The maximum catheterized volume per day was calculated using all available (non-zero) catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days were concurrent. The maximum value was calculated separately for each measuring day and the mean of these two values was used. Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Average First Morning Catheterized Volume The first morning catheterized volume was the volume associated with the first morning catheterization. The average first morning catheterized volume was calculated as the average of the available first morning catheterized volumes recorded for the 2 measuring days in the diary, whether or not these 2 days are concurrent. Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Secondary Change From Baseline to Weeks 3, 6, 9, 12, 24, 36 and 52 in Mean Number of Periods Between the Clean Intermittent Catheterizations (CICs) With Incontinence Per 24 Hours Participants were required to have 4-6 CICs per day on a schedule fixed for the duration of the study. To calculate the number of periods between CICs with incontinence in a diary day, the diary day was divided into periods between CICs (i.e. inter-CIC periods). The hour period, rather than the exact time, of each CIC and incontinence episode was recorded in the diary. When an incontinence episode and a CIC were marked in the same hour period, the incontinence episode was counted as occurring prior to the CIC (when the bladder had not yet emptied), rather than after it (when the bladder had recently been emptied), i.e. the inter-CIC period ended with the hour in which the CIC was recorded. The mean number of periods between CICs with incontinence per 24 hours was the number of periods between CICs when incontinence occurred, divided by the total number of valid diary days. Baseline and Weeks 3, 6, 9, 12, 24, 36, 52
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day at Baseline For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Baseline visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 3 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 3 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 6 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 6 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 9 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 9 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 12 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 12 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 24 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 24 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 36 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 36 visit
Secondary Percentage of Days With Catheterizations for Each Hour of 24 Hour Day During Week 52 For each one hour period of the 24 hour day, the percentage of days with catheterization was assessed as the number of days with catheterization occurring within the one hour period divided by the number of valid diary days over all subjects. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 52 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day at Baseline Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Baseline visit
Secondary Percentage of Days With of Incontinence for Each Hour of 24 Hour Day During Week 3 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 3 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 6 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 6 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 9 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 9 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 12 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 12 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 24 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 24 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 36 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 36 visit
Secondary Percentage of Days With Incontinence for Each Hour of 24 Hour Day During Week 52 Incontinence was defined as leakage where a diaper is not used, or dampness where a diaper is used. For each one hour period of the 24 hour day, the percentage of days with incontinence was assessed as the number of days with incontinence occurring within the one hour period divided by the number of valid diary days over all participants. Each participant contributed to up to three days of valid diary data for each visit. 3 days prior to Week 52 visit
Secondary Change From Baseline to Week 24 and 52 in Infant and Toddler Quality of Life Short Form-47 Questionnaire (ITQoL SF-47) - Overall Health Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Physical Abilities Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Growth and Development Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Pain Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Temperament and Moods Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Behaviour Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - General Health Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Change in Health Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Emotional Impact Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Parent-Time Impact Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
Secondary Change From Baseline to Week 24 and 52 in ITQoL SF-47 - Family Cohesion Impact Score The ITQoL SF-47 consisted of 47 individual items and was filled in by the child's parent. The individual items are based on Likert scales with either 5 responses (coded as 1 through to 5) or 4 responses (coded as 1 through to 4). From subsets of these coded values, 11 scales are derived: overall health, physical activities, development, discomfort, moods and temperaments, perceptions of current past and future health and perception of changes. Each scale score ranges from 0 (worst possible) to 100 (best possible). Baseline and Weeks 24, 52
See also
  Status Clinical Trial Phase
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Completed NCT02199626 - SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Phase 4
Recruiting NCT04679792 - Postual Control in Pediatric Chiari I Malformation
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Not yet recruiting NCT02182648 - Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction Phase 4
Active, not recruiting NCT04176640 - Quantifying Brain Injury on Computed Tomography in Hospitalized Children
Active, not recruiting NCT06146452 - Micronutrient Status in Pediatric Palliative Care
Completed NCT04041180 - Impact on the Length of Stay in Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: .
Not yet recruiting NCT06165003 - Examination of Nurses' Use of Broselow Tape in Non-resuscitation Pediatric Emergency Department Practices N/A
Recruiting NCT02286297 - Pediatric Endotracheal Intubation During Resuscitation N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Recruiting NCT00265772 - Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Phase 4
Completed NCT04106063 - A New Speech, Spatial, and Qualities of Hearing Scale Short-Form for Deaf Children
Not yet recruiting NCT06376643 - Augmented Reality to Support Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05511233 - ERAS Protocol in Newborns: CARES Study N/A
Not yet recruiting NCT04127968 - Efficacy and Safety of Vitamin A Treatment for Children With Sepsis N/A
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Recruiting NCT05909878 - Virtual Reality Distraction for Anxiety (VR-IMAGINE at HSJ) N/A
Recruiting NCT04988516 - Virtual Reality Distraction for Anxiety (VR-IMAGINE) N/A